Mechanisms of Amylin/Leptin Synergy in Rodent Models
Victoria F. Turek, Jonathan D. Roth(Rutgers, The State University of New Jersey), Guibao Gu(Arena Pharmaceuticals (United States)), Peter S. Griffin, Ambrose A. Dunn-Meynell(Rutgers, The State University of New Jersey), Calvin Vu, David G. Parkes(Amplyx Pharmaceuticals (United States)), Boman G. Irani(Rutgers, The State University of New Jersey), James L. Trevaskis, Barry E. Levin(Rutgers, The State University of New Jersey), Carrie Wittmer(Amplyx Pharmaceuticals (United States))
Cited by 136
Related Papers
Leptin responsiveness restored by amylin agonism in diet-induced obesity: Evidence from nonclinical and clinical studies
|Proceedings of the National Academy of Sciences|2008|433
Amylin: Pharmacology, Physiology, and Clinical Potential
|Pharmacological Reviews|2015|395
Diet-induced mouse model of fatty liver disease and nonalcoholic steatohepatitis reflecting clinical disease progression and methods of assessment
|American Journal of Physiology-Gastrointestinal and Liver Physiology|2013|294
Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice
|American Journal of Physiology-Gastrointestinal and Liver Physiology|2012|278